Lexeo Therapeutics IncNASDAQ:LXEO
- LAST PRICE12.5000
- TODAY'S CHANGE (%)0.3400 (2.7961%)
- Bid / Lots4.8500/ 2
- Ask / Lots15.0800/ 1
- Open / Previous Close12.3700 / 12.1600
- Day Range
- 52 Week Range
- Volume377,218
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LXEO |
|---|---|---|
| 09:32 ET | 200 | 12.37 |
| 09:34 ET | 100 | 12.36 |
| 09:38 ET | 200 | 12.18 |
| 09:52 ET | 300 | 12.35 |
| 10:06 ET | 100 | 12.24 |
| 10:10 ET | 200 | 12.42 |
| 10:12 ET | 200 | 12.245 |
| 10:17 ET | 600 | 12.335 |
| 10:21 ET | 100 | 12.48 |
| 10:32 ET | 100 | 12.515 |
| 10:35 ET | 100 | 12.415 |
| 10:44 ET | 700 | 12.67 |
| 11:09 ET | 100 | 12.76 |
| 11:11 ET | 300 | 12.55 |
| 11:18 ET | 100 | 12.76 |
| 11:22 ET | 100 | 12.645 |
| 11:24 ET | 920 | 12.76 |
| 11:42 ET | 400 | 12.605 |
| 11:44 ET | 100 | 12.61 |
| 11:47 ET | 600 | 12.85 |
| 11:51 ET | 100 | 12.855 |
| 11:56 ET | 100 | 12.86 |
| 11:58 ET | 13080 | 12.5 |
| 12:03 ET | 2300 | 12.5 |
| 12:07 ET | 5110 | 12.45 |
| 12:09 ET | 1000 | 12.49 |
| 12:12 ET | 100 | 12.47 |
| 12:30 ET | 400 | 12.455 |
| 12:38 ET | 200 | 12.455 |
| 12:39 ET | 2900 | 12.445 |
| 12:41 ET | 1313 | 12.54 |
| 12:43 ET | 716 | 12.525 |
| 12:48 ET | 900 | 12.5 |
| 12:52 ET | 200 | 12.46 |
| 12:54 ET | 600 | 12.46 |
| 12:56 ET | 616 | 12.48 |
| 01:01 ET | 3354 | 12.45 |
| 01:03 ET | 200 | 12.4 |
| 01:08 ET | 100 | 12.41 |
| 01:12 ET | 199 | 12.41 |
| 01:15 ET | 701 | 12.45 |
| 01:26 ET | 100 | 12.45 |
| 01:33 ET | 100 | 12.45 |
| 01:35 ET | 100 | 12.425 |
| 01:37 ET | 600 | 12.42 |
| 01:39 ET | 800 | 12.435 |
| 01:44 ET | 100 | 12.43 |
| 01:46 ET | 2969 | 12.45 |
| 01:50 ET | 2414 | 12.45 |
| 02:00 ET | 15080 | 12.56 |
| 02:06 ET | 100 | 12.5 |
| 02:08 ET | 13300 | 12.475 |
| 02:09 ET | 200 | 12.435 |
| 02:13 ET | 100 | 12.405 |
| 02:18 ET | 300 | 12.405 |
| 02:20 ET | 100 | 12.405 |
| 02:22 ET | 200 | 12.395 |
| 02:27 ET | 100 | 12.3981 |
| 02:29 ET | 16799 | 12.3 |
| 02:31 ET | 1100 | 12.33 |
| 02:33 ET | 4776 | 12.42 |
| 02:36 ET | 1196 | 12.5 |
| 02:45 ET | 900 | 12.5 |
| 02:47 ET | 200 | 12.5 |
| 02:54 ET | 400 | 12.5 |
| 03:02 ET | 300 | 12.5 |
| 03:12 ET | 136 | 12.515 |
| 03:27 ET | 12430 | 12.49 |
| 03:30 ET | 31817 | 12.21 |
| 03:32 ET | 10660 | 12.47 |
| 03:36 ET | 7600 | 12.42 |
| 03:38 ET | 7927 | 12.385 |
| 03:39 ET | 9970 | 12.36 |
| 03:41 ET | 38317 | 12.5 |
| 03:43 ET | 22599 | 12.5 |
| 03:45 ET | 25638 | 12 |
| 03:48 ET | 5723 | 12.245 |
| 03:50 ET | 1190 | 12.25 |
| 03:52 ET | 26690 | 12.25 |
| 03:54 ET | 2700 | 12.25 |
| 03:56 ET | 15897 | 12.43 |
| 03:57 ET | 1800 | 12.5 |
| 03:59 ET | 18994 | 12.5 |
Apr 22, 2024
Apr 16, 2024
DJ Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy, from 7:49AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:49AM ET on Tuesday Apr 16, 2024 by Dow JonesLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy, from 7:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lexeo Therapeutics Inc | 411.8M | -4.6x | --- |
Larimar Therapeutics Inc | 410.9M | -7.7x | --- |
ACELYRIN Inc | 419.4M | -0.4x | --- |
Tourmaline Bio Inc | 402.1M | -1.5x | --- |
LENZ Therapeutics Inc | 401.4M | -1.0x | --- |
Annexon Inc | 423.1M | -2.6x | --- |
Company Information
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Contact Information
- Headquarters
- 345 Park Avenue South, Floor 6NEW YORK, NY, United States 10010
- Phone
- 212-547-9879
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Steven Altschuler
- Chief Executive Officer, Director
- R. Nolan Townsend
- Chief Technical Officer
- Paul Mccormac
- Chief Legal and Administrative Officer
- Jenny Robertson
- Chief Scientific Officer
- Eric Adler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $411.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.69 |
Book Value | $4.26 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
